Table 3.
Cardiac phenotypic modifications
| Morphology | WT | KO | WTD | KOD |
| Young adult (1 mo) | ||||
| Heart/body weight (mg/g) | 5.2 ± 0.4 | 5.3 ± 0.6 | 5.2 ± 0.5 | 6.2 ± 0.8a |
| Body weight (g) | 17.4 ± 2.0 | 17.3 ± 2.2 | 17.3 ± 2.0 | 17.2 ± 1.5 |
| Adult (3 mo) | ||||
| Heart/body weight (mg/g) | 5.6 ± 0.6 | 7.0 ± 0.8d | 5.4 ± 0.7 | 6.7 ± 0.8d |
| Body weight (g) | 30.1 ± 2.5 | 30.3 ± 2.2 | 29.4 ± 2.2 | 28.4 ± 2.2 |
| Cardiotoxic gene groups | ||||
| Dilation (ratio) | - | 3 | 1.8 | 2.8 |
| Hypertrophy (ratio) | - | 9.9 | 3.3 | 6.5 |
| Damage (ratio) | - | 3.7 | 3.7 | 3.6 |
| Cell death/ necrosis (Ratio) | - | 3.0 | 4.3 | 3.1 |
| Measured activity | ||||
| Caspase 3 (arbitrary units) | 0.25 ± 0.17 | 0.44 ± 0.17 | 0.84 ± 0.09a | 0.35 ± 0.07 |
| Autophagic vacuolization (n°) | 0.07 ± 0.1 | 0.35 ± 0.3 | 0.2 ± 0.2 | 2.4 ± 2.1a |
| Serum cTnI (mg/mL) | 0.15 ± 0.1 | 3.6 ± 1.5 | 0.7 ± 0.2 | 14.5 ± 4.2a |
| LVDP (mmHg) | 109.2 ± 7.1 | 42 ± 8.2a | 94.5 ± 5.5 | 31.5 ± 5.4a |
| Tau ½ | 37.4 ± 1.9 | 38.1 ± 4.9 | 36.1 ± 3.1 | 34.6 ± 2.9 |
Morphological and biochemical modifications studied in the aggravated cardiotoxic condition of the doxorubicin-treated-ventricular specific erbB4-KO mouse model. Summary of hypertrophic-associated morphological changes determined in mouse at the age of 1 and 3 mo, group of differentially expressed genes clustered into a wide-range of cardiotoxic conditions, biochemical activities associated to cell death and of physiological systolic and diastolic parameters are represented as discussed in the text.
a
P < 0.05 vs WT,
d
P < 0.01 vs WT and WTD. WTD: Doxorubicin-treated wildtype; KOD: Doxorubicin-treated erbB4-KO; WT: Treated wildtype.